QUESTIONS UNDER STUDY: Drug-drug interactions (DDI) are considered a risk factor in medication safety and computerised alerting tools are increasingly promoted and implemented in order to detect and minimise DDI. As only little is known about the frequency and nature of DDI in hospitalised patients in Switzerland as well as about the usefulness of current alerting systems, this analysis based on a computerised medication record in a typical regional hospital setting was performed. METHODS: All inpatients with at least one drug prescription between 2006 and 2010 were included. A total of 1,654,987 prescriptions were analysed with regard to the maximal seriousness level of DDI between each added prescription versus the existing prescription and with regard to all underlying DDI. RESULTS: On average, each inpatient received 16 different drugs including on-demand prescriptions and encountered 5 DDI. A total of 27% of all prescriptions caused DDI. Within the last 12 months, 5% of all DDI were classified in category 1 (contraindicated), 3% in category 2, 53% in category 3, 8% in category 4 and 31% in category 5. The vast majority of DDI were caused by a very limited number of drugs. DISCUSSION: Drug-drug interactions were very frequent and were very stable over the years studied, involving on average 27% of all prescriptions and 44% in internal medicine. Only a very limited amount of drugs were responsible for the vast majority of DDI, especially when the most severe categories of DDI were considered. Most of the severe DDI alerts could be automatically handled, if for example laboratory values could be taken into account. The DDI database should ideally be supplemented by information enabling more sophisticated computerised support in order to deliver more reasonable results from DDI checks.
Introduction
Drug-drug-interactions are considered a risk factor in medication safety and represent a relevant part of adverse drug events. As they are potentially preventable in many cases, and physicians and information systems designers are looking for strategies to detect, categorise and, consequently, prevent drug-drug-interactions (DDI). Adverse drug events (ADE) per se account for 19% of all adverse events [1] , and 5-26% out of these are generated by DDI [2] [3] [4] . Due to multi-morbidity and polypharmacy, inpatients are especially prone to ADE [5] . A large university hospital based study detected DDI in 28% of all inpatients [6] and there seems to be an independent association between DDI and the length of stay, as well as the cost of a hospital stay [7] . Thus, handling DDI could enhance patient safety and reduce costs especially in the inpatient setting. In recent years, efforts to increase patient safety with regard to the medication process have mainly focused on computerised physician order entry (CPOE). Within this area, decision support in terms of alerts (e.g., drug-allergyalerts, drug-dosage-alerts, drug-drug interaction alerts DDI-A) increasingly controls or influences the prescription process of physicians. However, the value of DDI alerting is still very unclear as only limited data on the prevalence and incidence of DDI in certain countries exist, the clinical impact of drug interactions is often vague and -with current databases -only interactions between two single drugs can be tested. Unfortunately, this usually leads to a huge gap between posted alerts (e.g., drug-drug-interaction alerts DDI-A) and alerts being accepted by physicians, therefore leading to compliance problems. A recent Dutch study, for example, showed that 91% of all drug related alerts were overridden by clinicians [8] , and the overriding rate climbed to 98% when only DDI alerts were considered, questioning the sensibility of this support itself. Similar rates are reported elsewhere [9] with peer reviewers even attesting a 96%-correctness with regard to overruling. Therefore, DDI alerting does not seem to match everyday routine appropriately. Despite the fact that knowledge of underlying DDI is crucial when decision support is warranted, only little is known about the distribution of DDI in Switzerland. The DDI prevalence with regard to different departments or to specific drug pairs and differences between university and community based hospitals are particularly unknown. Furthermore, most studies have considered only small to medium sized patient samples, focused on specific patient groups or used only trigger events for identifying potential DDI. In the most commonly used Swiss DDI database (GALDAT/HOSPINDEX), interactions are actually defined in a seriousness index consisting of six (until 2009 only five) categories (table 1) . The purpose of this study was twofold. The first purpose was to gain an overview of the frequency, nature and stability in time of DDI in a Swiss primary and secondary acute care hospital, and secondly, with respect to potential prevention strategies, to identify the most common single drugs creating the most serious interactions. In the hospital sites studied, CPOE as part of the fully electronic patient record includes routine checks for DDI since 2004 and all data concerning prescriptions and drugs involved in DDI have been registered in parallel since the beginning. Representing the daily practice of a typical Swiss non-university hospital, this analysis included more than 10 6 prescriptions over a five year period. The results could delineate current settings in Swiss hospitals concerning (preventable) adverse drug events and, furthermore, could enhance a critical appraisal of the DDI management especially in terms of decision support in electronic prescribing tools.
Materials and methods
The Spital STS AG is a publicly owned primary and secondary acute care regional hospital group with 310 inpatient beds distributed over three distant locations, caring for about 15,000 inpatients a year. As part of the fully electronic inpatient record, CPOE has been used since 2002 and has included routine checks for DDI since 2004. The DDI data are based on the official Swiss database GALDAT/ HOSPINDEX™. Until 2009, this database defined five distinct categories of DDI seriousness, with category 1 being the most severe and category 5 being the least severe (table 1). In November 2009, an update and extension of the database was published, adding a sixth category and defining the five other categories in a more action-oriented manner, principally based on the propositions of Hansten et al. [10] and aligned with the German ABDA database. With the CPOE system in use, adding new prescriptions to the medication record routinely starts a screening for DDI. The screening involves the whole medication record including the added drug(s), the current medication and all on-demand drugs and works without any user interruption. Two distinct pieces of information are stored during this process: the maximal DDI seriousness category (1-6) appearing during the prescription and all involved drugs identified by the specific drug code (pharmacode). The former information has primarily a screening character, whereas the latter can be used to test for all present drug interactions. Additionally, available DDI checks (e.g., on-demand checks) do not influence the outlined data storage. The current analysis included every prescription in all inpatients of the hospital group during the years 2006 to 2010. Medication records were included if at least one drug was prescribed. The incidence of the maximal seriousness category detected during the real-time DDI check was outlined for every year and additionally separated concerning the three distinct hospital clinics. Restricted to 2010 and the three most important categories, all drug pairs creating DDI are outlined. As newly added drugs are stored together with previously existing ones during the prescription process, cross checking these data can identify all drug pairs creating DDI. This analysis was performed retrospectively and results in more DDI than the check for the maximal level itself as more than one drug pair can create interactions of the same DDI category. As seriousness category four, five and six are clinically of little or no importance in general, only categories 1-3 are outlined in this analysis. 2010 was chosen due to the fact that it is a 12 month period following the introduction of the new classification database.
Results
On average, as shown in table 2, every inpatient stay results in 16 prescriptions of different drugs regardless of the department (13 prescriptions excluding on-demand drugs, data not shown in table 2). This figure remained quite steady over the years studied. The amount of prescribed drugs in relation to the different departments was steady as well, with the internal medicine department accounting for the highest amount (20) and the gynaecology/obstetrics department for the lowest (11) . Every inpatient stay encountered 5 DDI on average. Out of all prescriptions, 26-29% (2006-2010) created a DDI alert (DDI-A) independently of the DDI seriousness category (based on table 2). In internal medicine, 40-46% of all prescriptions created a DDI-A, compared to 20-24% in the surgical department and 6-8% in the gynaecology/ obstetrics departments. Between 2006 and 2009 and over all departments, the vast proportion of DDI-A (60-69%) corresponded to category 2. In these three years, category 2 and category 3 DDI-A accounted for 95% of all alerts. After the publication and immediate implementation of the revised DDI database in November 2009, a shift from category 2 interactions to category 5 interactions was noticed with a transition period in 2009. In 2010, the vast proportion of DDI-A corresponds to category 3 (51%) while 31% of DDI-A are due to the newly Table 1 The seriousness classification used within the currently used Swiss drug-drug-interaction DDI database GALDAT. A total of 69% of all category 1 DDI were due to the potassium-spironolactone interaction, and an additional 22% were due to the interaction between potassium and parenteral nutrition products. The clopidogrelesomeprazol interaction accounted for 13% of all category 2 DDI, the levodopa-metoclopramid DDI for 8% and the amiodarone-quetiapin DDI for 6%, whereas all other drug pairs did not exceed a 5% cut-off each. Table 4 indicates the top ten drugs involved in DDI alerts of category one to three: the top three drugs in each category together accounted for 61% of all DDI in 2010 (41856 out of 68376 DDI, data not outlined in table 4).
Discussion
The frequency and nature of medication errors and adverse drug events in general have been widely studied in the last two decades [11] [12] [13] . Additional data indicate a prevalence of hospital admissions in adults or elderly patients due to or associated with ADE to be as much as 2-10% [2, [14] [15] [16] . Efforts to reduce errors in the medication process and thus to increase medication safety include the implementation and usage of CPOE systems. As adverse drug events are frequent and DDI are considered as relevant factors creating ADE, implementation of an alerting system for DDI and other preventable ADE has emerged over the years. As no internationally accepted and distributed classification system of DDI exists, many regions or countries have their own DDI databases in use. From experiences outside Switzerland, we can assume that the average number of alerts per admission is 4-8 [6] , and that roughly 10 to 40% of all prescriptions in inpatients create DDI, independently of the seriousness category. In many cases, few drug combinations account for more than two thirds of all alerts. Furthermore, up to 50-70% of inpatients show DDI at admission or discharge [17] [18] [19] [20] . Serious problems have been reported concerning physicians' compliance with alerts during the prescribing process. Emphasising this area of concern, van der Sijs et al. [8] reported a global overruling rate of 91% concerning alerts in the medication process and even a 98% overruling rate when DDI alerts were considered. However, system design and tiering of alerts to the clinical situation have the potential to increase compliance dramatically [21, 22] .
In this study, all prescriptions performed in a five year period in a regional hospital setting were analysed with regard to DDI. On average, 16 different drugs were prescribed for every inpatient (13 if on-demand drugs were excluded). DDI were identified in 27% of all prescriptions. When broken down to distinct departments, clear differences could be seen between internal medicine (44%) and gynaecology (7%) for example, reflecting the very nature and the demography of patients in these specialities. These Table 2 All (1) 27 (2) 81 (5) 656 (37) 344 (20) 650 (37)
Original article
Swiss Med Wkly. 2012;142:w13522 results were very stable over the years and well in line with previous results in other countries although the classification system is different. Due to changes in the DDI database, a shift from category 2 to a newly created category 5 could be noticed in 2009. Within the most relevant seriousness category, the majority of registered DDI (and therefore most of the alerts being presented to the prescribers in a disruptive manner) were due to the interaction between potassium and potassiumsparing agents, primarily spironolactone. Although hyperkalemia can be life threatening, many patients in need for this combination will in fact have a hypokalemia and will suffer from chronic heart failure for example. Therefore, the effect of the combination therapy is likely to be intended rather than unintentional. Furthermore, potassium levels are likely to be under strict control in an inpatient setting. The same situation might be present in the second most frequent DDI with the highest seriousness level, the interaction between potassium and parenteral nutrition. These two DDI alone accounted for 90% of all category 1 interactions and have major implications for the prescriber, as the most dangerous DDI are usually presented in an interruptive manner. In category 2 DDI, only the interaction clopidogrel/esomeprazol and levodopa/metoclopramid exceeded a 10% cut-off. In category 3, phenprocoumon, metoprolol, prednison and acetylsalicate were the only drugs accounting for more than 5% of all DDI-A. These results lead to several key messages. Firstly, the frequency as well as the nature of DDI show a high stability over years and a huge impact of a very limited number of drugs on the overall DDI alert rates, especially in the two most important seriousness categories. Secondly, a discrepancy between the most frequent DDI and their clinical significance concerning the individual patient has to be Table 3 The frequency and nature of drug-drug-interactions (DDI) in 2010 over all clinics, separated in severity categories 1, 2 and 3. As more than one drug pair can result in a same DDI category alert within a given prescription, the number of drug pairs exceeds the number of DDI outlined in table 2. In category two and three, only the top ten drug pairs are indicated. In category one, four drug-pairs account for 97% of all DDI. In category two and three, the top ten DDI account for 52% and 57% of all DDI respectively. For category 3, due to the huge amount of different drugs used, class effects are taken together, where appropriate (e.g., angiotensin-converting enzyme inhibitors ACE). +Each single DDI not specifically outlined (others, number of specific DDI in brackets indicated) accounts for less than 2% of all DDI. *Nutriflex is a commercially available, parenteral nutrition solution (ATC B05BA10). ACE: angiotensin-converting enzyme inhibitor ARB: angiontensin-receptor blocking agent NSAID: non-steroidal anti-inflammatory agent
Category 1 DDI Frequency of DDI (%)
Potassium-spironolacton 2,894 (69)
Spironolacton-nutriflex* 936 (22) Ceftriaxon-nutriflex* 146 (3)
Atorvastatin-clarithromycin 117 (3)
Others+ ( Clarithromycin-salmeterol 57 (2) discussed. Thirdly, the vast majority of alerts could be prevented by taking into account the current clinical context, for example laboratory values like potassium levels. By doing this, up to 90% of category 1 DDI could potentially be suppressed, leading to far less alerts for the prescribers and most probably to a less intense alert fatigue and thus an increased compliance with DDI alerts. Fourth, some DDI are stated although they only affect a certain patient category (e.g., DDI between parenteral nutrition and ceftriaxon, being only relevant in children). Fifth, there seems to be a gap between the appearance of DDI as defined in the official database and the clinical expertise, where for example DDI involving anticoagulation treatment, drug levels or drug resorption problems due to chelation are often cited as a major concern. Additionally, the implication of many DDI is discussed controversially like the clopidogrel-esomeprazol interaction for example. The strength of this study is the inclusion of all prescriptions in a period of five consecutive years. Due to CPOE and the chosen implementation, a complete workup of prescriptions was possible, making unwarranted influences by individual physicians, short term trends in pharmacotherapy or dependency of manually performed DDI checks very unlikely. Due to this, the outlined data are very representative for other Swiss hospitals in this setting. Furthermore, drugs on an as-needed basis can be included as well, reflecting a safety issue during drug administration. The study has some limitations as well. Firstly, inclusion of on-demand prescription might show a certain correlation to existing order sets (e.g., metoclopramid on a on-demand basis for nausea). As on-demand orders are included as well, the overall quantity of DDI could be overestimated with regard to permanent orders. However, it is a fact that on demand drugs could be used anytime and DDI-A should take this into account. Secondly, as the prescribing process initiates automatic DDI checking, ordering single drugs instead of multiple drugs in the same prescribing process could theoretically lead to an increase of DDI alerts, as the trigger event for DDI checking is the transcription of added drugs to the existing medication administration record. However, this overestimation should not affect the distribution within the drugs but only the overall amount of DDI. Independently of the current study design it has to be kept in mind that current checks for DDI can only handle single drug pairs. Knowledge about DDI in more than two involved drugs is scarce and corresponding databases are even absent. Thus, current analysis of polypharmacy is reduced to DDI between two specific drugs.
Facing the results of the current analysis, we can assume that the current Swiss DDI database should be supplemented by structured, drug specific data on affected patient groups (e.g., adults, children), clinical relevance (e.g., in contrast to in vitro relevance), clinical evidence for the outlined DDI and, most of all, strategies concerning alert handling (e.g., laboratory values including cut-offs). This additional information could enhance critical appraisal with regard to DDI and enable system designers to cope with DDI alerts in a differentiated manner. By doing this, Table 4 The most frequent drugs involved in DDI alerts within the DDI categories 1-3 and during 2010 are outlined. In category 1, drugs creating more than 50 DDI-A are indicated. In category 2 and 3 only the top ten drugs are indicated.
Category 1 DDI Drug involved in DDI (%)
reasonable support concerning DDI could be implemented in current CPOE systems. Otherwise, as outlined by previous studies, most DDI alerts will be overridden due to the bad match between prescribed drugs and the relevance of the alert facing the clinical situation. Overriding rates of more than 90% and, furthermore, the fact that overriding seems to be appropriate clearly indicates over-alerting, and increases not only alert fatigue but also the chance of missing relevant DDI due to lowered overall attention. CPOE has shown considerable potential to improve prescribing quality and patient safety, given a professional and seamless integration into clinical workflows. Adding decision support in terms of DDI checking however -although technically simple -is a challenging task facing the existing database and the multifaceted clinical settings. Efforts have to be undertaken to cope with the existing data in order to minimise noise by unnecessary alerting and further supplement available pharmacological database in order to deliver a reasonable basis for further decision support.
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